Viral hepatitis and liver transplantation

Area of Science:

• Hepatology
• Transplantation Immunology
• Virology

Background:

• Hepatitis C is a primary indication for liver transplantation, with universal allograft reinfection and accelerated disease progression.
• Hepatitis B reinfection prevention has seen significant advances, achieving excellent outcomes with graft infection rates below 10%.

Purpose of the Study:

• To review current strategies and future challenges in managing viral hepatitis in liver transplant recipients.
• To evaluate the efficacy of antiviral therapies in preventing and treating hepatitis C and B recurrence post-transplantation.

Main Methods:

• Review of existing literature on antiviral therapy for hepatitis C and B in liver transplant patients.
• Analysis of outcomes related to preemptive, post-transplant, and treatment of established disease for hepatitis C.
• Assessment of prevention strategies for hepatitis B, including immunoglobulin and nucleoside analogs.

Main Results:

• Preemptive antiviral therapy for hepatitis C post-transplant has yielded disappointing results.
• Treatment of established hepatitis C with pegylated interferon and ribavirin shows sustained virologic response rates of 25-40%.
• Hepatitis B reinfection rates are now excellent (<10%) due to advances in prevention.

Conclusions:

• Antiviral therapy before transplantation may reduce hepatitis C reinfection.
• Future strategies should focus on optimizing antiviral use to prevent transplantation, manage resistance, and refine hepatitis B prophylaxis.